Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
ALNY Stock Chart & Stats
$320.66
-$0.58(-0.25%)
At close: 4:00 PM EST
$320.66
-$0.58(-0.25%)
Day’s Range― - ―
52-Week Range$205.87 - $495.55
Previous CloseN/A
Volume78.96K
Average Volume (3M)1.38M
Market Cap
$42.53B
Enterprise Value$42.15B
Total Cash (Recent Filing)$2.91B
Total Debt (Recent Filing)$1.28B
Price to Earnings (P/E)166.0
Beta1.02
Next Earnings
Apr 30, 2026EPS Estimate
0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.82
Shares Outstanding132,623,140
10 Day Avg. Volume1,055,704
30 Day Avg. Volume1,384,037
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)66.01
Price to Sales (P/S)14.03
P/FCF Ratio111.94
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue11.35
Enterprise Value/Gross Profit13.89
Enterprise Value/Ebitda89.17
Forecast
1Y Price Target
$455.84Price Target Upside42.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)6.93
Revenue Forecast (FY)$5.56B
Bulls Say, Bears Say
Bulls Say
Commercial Momentum And Market ShareAmvuttra's launch has shown stronger-than-expected commercial momentum and increasing share in the transthyretin treatment market, supporting sustained product revenue growth.
Pipeline Progress And Clinical ReadoutsA broad pipeline with multiple late-stage programs and upcoming clinical readouts could materially expand future revenue streams and raise the company's long-term growth profile.
Profitability And Cash PositionAchievement of GAAP profitability and accumulation of cash reserves indicates improving operating leverage and provides financial flexibility to support growth investments.
Bears Say
Planned R&D And SG&A IncreasesSubstantial planned increases in R&D and selling expenses raise the risk that operating costs will pressure near-term profitability until investments generate results.
Pricing Resets And International Revenue PressurePrice realignment in some markets and expected net price declines in the U.S. could weigh on international and domestic sales growth, limiting near-term revenue momentum.
Seasonal Shipping And Insurance Reauthorization EffectsFewer shipping weeks and insurance reauthorizations are expected to reduce recognized U.S. revenues and prescription volumes, creating temporary softness in reported sales.
Alnylam Pharma News
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $205.87 and its highest was $495.55 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $42.53B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Apr 30, 2026 which is in 52 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Feb 12, 2026. The company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.156 by -$0.336.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is 0.99.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 132,623,140 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of $0.82 in its last earnings report, missing expectations of $1.156. Following the earnings report the stock price went down -4.282%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in ALNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alnylam Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$455.84 (42.16% Upside)
$455.84 (42.16% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 276.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $18.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 15.1%
Last 30 Days ▼ 15.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.23%
12-Months-Change
Fundamentals
Return on Equity
73.28%
Trailing 12-Months
Asset Growth
16.82%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
ALNY Company Deck
ALNY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive outlook supported by transformational 2025 results — nearly $3B product sales (81% YoY), robust Q4 performance, GAAP profitability, a deep and advancing pipeline (three Phase 3 starts) and ambitious 2030 goals — while responsibly acknowledging near-term headwinds including margin pressure from royalties, expected mid-single-digit net price declines, Q1 phasing impacts (notably a ~ $25M international adjustment), and higher planned R&D/SG&A investments. Management provided clear 2026 guidance (product revenue $4.9B–$5.3B, TTR $4.4B–$4.7B) and articulated how platform, pipeline, and manufacturing scale underpin sustained growth. Overall, the positives (strong growth, profitability, pipeline depth, funded strategy) materially outweigh the manageable near-term challenges.View all ALNY earnings summariesALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
ALNY Stock 12 Month Forecast
Average Price Target
$455.84
▲(42.16% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---